The role of NAD+ metabolic reprogramming in colorectal cancer chemoresistance: mechanistic insights, clinical translation challenges and opportunities

To summarize the molecular mechanisms by which NAD+ metabolic reprogramming drives chemoresistance in colorectal cancer.

NAD+ metabolic reprogramming is a critical driver of chemoresistance in colorectal cancer.
Key enzymes like NAMPT and SIRT1 play significant roles in maintaining NAD+ levels and promoting tumor cell survival.

NAD+ homeostasis is essential for colorectal cancer cells to evade chemotherapy-induced cell death.

Tumor metabolic heterogeneity complicates the clinical application of NAD+ targeting strategies.
Lack of dynamic monitoring technologies for NAD+ levels hinders effective treatment.
Insufficient tissue specificity of targeted drugs limits their efficacy.

The review provides insights into the mechanisms of NAD+ metabolic reprogramming in colorectal cancer.